← Back to Search

Insulin-Like Growth Factor 1 for Aging Skin

Phase < 1

Recruiting

Led By Jeffrey B Travers, MD, PhD

Research Sponsored by Wright State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 21-30 or 65 and older

Be older than 18 years old

Must not have

Currently on photosensitizing medications

History of skin infections

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 days

Summary

This trial is testing whether artificial sunlight affects young adult skin differently than older skin, and if older skin will respond to a drug injection the same as young skin.

Who is the study for?

This trial is for healthy adults aged 21-30 or 65 and older with white skin (Fitzpatrick types I and II). Participants must understand the procedures and risks. Those with allergies to lidocaine, serious health issues, on photosensitizing meds, diabetes, abnormal scarring history, skin infections, pregnancy/nursing or known photosensitivity cannot join.

What is being tested?

The study investigates how young adult versus geriatric skin responds to artificial sunlight (UVB). It will test if treating geriatric skin with an injection of IGF-1 makes it respond like young skin. The intervention includes exposure to UVB and possibly receiving an IGF-1 injection.

What are the potential side effects?

Potential side effects may include reactions similar to sunburn from UVB exposure such as redness or pain. There might also be local reactions at the injection site if treated with IGF-1 like swelling or discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am either between 21-30 years old or 65 and older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am taking medication that increases my sensitivity to light.

Select...

I have had skin infections in the past.

Select...

I have diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in expression genes involved in protecting skin cells from UVB damage in younger skin and geriatric skin injected with IGF-1 from baseline

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Geriatric AdultActive Control1 Intervention

Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.

Group II: Young AdultPlacebo Group1 Intervention

One small area of skin will undergo treatment with a small amount of UVB.

0 / 4Eligibility criteria met